Advertisement
Mr. Ehrlichman, who pioneered outpatient real-time cardiac telemetrytechnology and call center monitoring as Chief Executive Officer and Presidentof Cardiac Telecom Corporation, will report directly to Signalife's ChiefExecutive Officer, Mr. Rowland Perkins. Mr. Ehrlichman's successful history isknown and is public record, including for example his stint at Tartan, Inc., acompany which he turned around after ten-years of losses, and later was soldto Texas Instruments.
Advertisement
Signalife also announced that it has moved its principal headquarters toLos Angeles -- where it was originally based -- in-house with the company'slaboratory, R&D and IT operations, and close to the company's manufacturingoperations in Ventura, California. Signalife has also expanded the squarefootage of its Los Angeles facilities in view of numerous additional staffmembers the company envisions it will add in the coming days in connectionwith its anticipated sales and marketing activities.
Dr. Lowell T. Harmison, Signalife's prior Chief Executive Officer andPresident, has taken an indefinite leave of absence as both an officer anddirector during which he is expected to consult to the company, as best hecan, on a variety of matters.
In view of such leave, Mr. Rowland Perkins, previously Signalife's InterimAdministrative Chief Executive Officer, will assume all duties of the officeof Chief Executive Officer. Rowland Perkins, Signalife's Chief ExecutiveOfficer, commented: "I am personally excited and gratified to have somebody ofLee Ehrlichman's experience and talents now take command and control to expandon the many achievements of Dr. Harmison. On behalf of my colleagues, I amthankful to Dr. Harmison for all his hard work and efforts throughout thehistory of the company. I look forward to working with Dr. Harmison in hisfuture advisory roles for Signalife."
Mr. Perkins said that he anticipates additional changes to the make-up ofits Board of Directors, and other developments, later this week. An employmentcontract with Mr. Ehrlichman has been agreed to in principle and is expectedto be executed over the next several days.
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring,detection and prevention of disease through continuous biomedical signalmonitoring. Signalife uses its patented signal technology to design anddevelop medical devices, therapies and/or technologies that simplify andreduce the costs of cardiovascular disease.
Signalife, Inc. is traded on the American Stock Exchange under the symbolSGN. More information is located at www.signalife.com. Clear Data. TrustedResults.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknownrisks, which may cause Signalife's actual results in the future to differmaterially from expected results. Factors which could cause or contribute tosuch differences include, but are not limited to, failure to complete thedevelopment and introduction of heart monitoring and other biomedical devicesincorporating Signalife's technology procure market acceptance for theseproducts, failure to obtain federal or state or governmental or internationalregulatory approvals governing heart monitoring and other biomedical devicesincorporating Signalife's technology, failure to obtain import and exportcapabilities in the various countries containing buyers and re
